Webinar Registration Alert: Novel Platforms for Preclinical Antibody Discovery | #ai de novo antibody sequence generation

科学和技术

Webinar Registration Alert: Novel Platforms for Preclinical Antibody Discovery

Traditional discovery methodologies rely on isolating candidate molecules from a randomized biological library.

Webinar Alert: Bridging the Preclinical Gap with Next-Generation Brain and Tumor Organoids | #brain and Tumor Organoids

科学和技术

Webinar Alert: Bridging the Preclinical Gap with Next-Generation Brain and Tumor Organoids

For decades, translational medicine has faced a frustrating bottleneck: why do over 90% of oncology and neurology drug candidates that show dazzling success in preclinical lab testing ultimately fail when injected into human patients?

Breaking Traditional Barriers: Harnessing Multi-Organ-on-Chip and Gut-Lung Axis Models to Map the Neuroimmune Power of Live Biotherapeutic Products | #multi-Organ-on-Chip

科学和技术

Breaking Traditional Barriers: Harnessing Multi-Organ-on-Chip and Gut-Lung Axis Models to Map the Neuroimmune Power of L

The therapeutic landscape is undergoing a conceptual shift as researchers move beyond single-target drugs to embrace the systemic complexity of Live Biotherapeutic Products (LBPs).

Multidimensional Construction of EAE Animal Models: Advancing Multiple Sclerosis Drug Discovery | #eae Animal Model

科学和技术

Multidimensional Construction of EAE Animal Models: Advancing Multiple Sclerosis Drug Discovery

Multiple Sclerosis (MS) remains a primary focus of neuro-immunology due to its complex pathology and the diverse clinical manifestations observed in patients.

Taming the "Trojan Horse": Preclinical Safety Strategies and Off-Target Risk Mitigation for Solid Tumor ADCs | #antibody-Drug Conjugates

科学和技术

Taming the "Trojan Horse": Preclinical Safety Strategies and Off-Target Risk Mitigation for Solid Tumor ADCs

Antibody-Drug Conjugates (ADCs) have revolutionized oncology, earning their reputation as biological "Trojan horses."